MONTSERRAT CRISTINA GARRIDO MARTÍN

Dr. MONTSERRAT CRISTINA GARRIDO MARTÍN

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JGJaume Galceran
Jaume Galceran
AAAlberto Ameijide
Alberto Ameijide
NJNOURA JEGHALEF
NOURA JEGHALEF
AGANTONIA SÁNCHEZ GIL
ANTONIA SÁNCHEZ GIL
MGMarcela Guevara
Marcela Guevara
O(On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
Background: Childhood cancer survivors have a higher risk of developing malignancies later in life compared with individuals of similar age in the general population. In Spain, population-based evidence on second malignant neoplasms (SMNs) is limited. This study aimed to estimate survival following childhood cancer diagnosis and to assess the risk of SMNs in Spain. Methods: This population-based registry study used data from 12 cancer registries within the Spanish Network of Cancer Registries (REDECAN). All malignancies of sites and non-malignant central nervous system (CNS) tumors diagnosed before age 15 were included. Age-standardized incidence rates (ASIRw) for 2015–2019 were calculated. Five- and 10-year age-adjusted observed survival rates for 1990–1999 and 2000–2009 were estimated. SMN risk was assessed using standardized incidence ratios (SIRs) and excess absolute risks (EARs). Results: The ASIRw for 2015–2019 was 181.3 per million child-years. Ten-year survival increased from 71.3% in 1990–1999 to 75.5% in 2000–2009. The overall risk of developing an SMN was significantly elevated (SIR = 5.67) at 20 years. Conclusions: Although survival for childhood cancer in Spain was around 75% in 2000–2009, childhood cancer survivors remain at substantially increased risk of SMNs for at least two decades. Efforts to reduce treatment-related toxicity while maintaining survival gains are essential.

21 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JGJaume Galceran
Jaume Galceran
AAAlberto Ameijide
Alberto Ameijide
NJNOURA JEGHALEF
NOURA JEGHALEF
AGANTONIA SÁNCHEZ GIL
ANTONIA SÁNCHEZ GIL
MGMarcela Guevara
Marcela Guevara
MCMarià Carulla
Marià Carulla
Background: Childhood cancer survivors are more likely to develop cancer in adulthood than people of similar age in the general population. In Spain, there are no popula-tion-based studies on the risk of developing second cancers in people diagnosed with childhood cancer. The main objective of this study was to present recent survival rates fol-lowing a childhood cancer diagnosis in Spain and to investigate the risk of second malig-nant neoplasms (SMNs) in people diagnosed with childhood cancer between 1990 and 2009. Methods: This population-based registry study, devised by the Spanish Network of Cancer Registries (REDECAN), collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 15 years in populations covered by 12 cancer registries of Spain. Age-standardised incidence rates (ASIRw) for the period 2015–19 were calculated per million childhood-years. Five-year and 10-year age-adjusted observed sur-vival rates, for the periods 1990-1999 and 2000–2009 were estimated. The risk of develop-ing SMNs was calculated using standardized incidence ratio (SIR), excess absolute risk (EAR). Age-specific incidence rates of SMN were also calculated. Results: During the pe-riod 2015-2019, the ASIRw was 181.3 per million child-years. The 10-year childhood sur-vival rate for both sexes combined increased from 71.3% to 75.5% between the 1990s and the 2000s. The relative risk of a SMN in people with a first childhood cancer diagnosed between 1990 and 2009 was 5.67 at 20 years after the diagnosis of the first cancer. Conclu-sion: In the 2000s, the 10-year survival rate for childhood cancer in Spain was around 75%, but survivors faced a high risk of developing a second cancer for at least 20 years af-ter their initial diagnosis. Efforts to reduce treatment-related toxicity are essential to miti-gate this long-term risk without compromising survival outcomes.